Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895044 | 0.89 | GPR119 (0.44) | GPR119ITGB3ITGA2BACP1 | |
| SCHEMBL22894951 | 0.87 | NR1H2 (0.51) | GPR119AVPR2ITGB3ITGA2BACP1 | |
| SCHEMBL22894952 | 0.87 | NR1H2 (0.51) | GPR119AVPR2ITGB3ITGA2BACP1 | |
| SCHEMBL22894953 | 0.87 | NR1H2 (0.42) | GPR119AVPR2 | |
| SCHEMBL22894955 | 0.87 | NR1H2 (0.42) | GPR119AVPR2 | |
| SCHEMBL20077312 | 0.86 | GPR119 (0.60) | GPR119 | |
| SCHEMBL20077328 | 0.85 | NR1H2 (0.44) | GPR119AVPR2ITGB3ITGA2BACP1 | |
| SCHEMBL22894988 | 0.85 | NR1H2 (0.44) | GPR119AVPR2ITGB3ITGA2BACP1 | |
| SCHEMBL22894974 | 0.84 | NR1H2 (0.43) | GPR119AVPR2ITGB3ITGA2BACP1 | |
| SCHEMBL22894975 | 0.84 | NR1H2 (0.43) | GPR119AVPR2ITGB3ITGA2BACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | GPR119 7/4885AVPR2 1787/4885CNR1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.